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Plasmodium falciparum, the organism responsible for the most prevalent and most 
virulent cases of malaria in humans, poses a major burden to the developing world. The parasite 
is increasingly developing resistance to traditional therapies, such as chloroquine, so the need to 
determine novel drug targets is more prevalent than ever. One such method involves targeting 
proteins unique to the malarial proteome that do not have homologues in humans. An especially 
promising group of targets are protein kinases, which are involved in many different biochemical 
pathways within the cell. Eukaryotic cell cycle progression is moderated by a family of protein 
kinases known as the cyclin-dependent kinases (CDKs). These kinases depend on the binding of 
a cognate regulatory unit (cyclin) in order to enter its activated state. Once activated, these 
cyclins then mediate phosphorylation events that are crucial to cell cycle advancement [1].  
Cyclin Dependent Kinases (CDKs) are common to most eukaryotes and are responsible 
for regulating the cell cycle of growth and proliferation. Proteins have been previously identified 
in Plasmodium that have sequence homology to traditional CDK and have a potential function to 
be classified as “CDK-like” kinases. Three kinases that fit this description are Plasmodium 
falciparum Kinase 5, 6, and mrk, or MO15- Related Kinase. These kinases are expected to have 
roles in both malarial growth and regulation of the cell cycle. Bacterial constructs were generated 
to express and purify recombinant forms of these kinases and potential substrates. Once the 
potential interactors were isolated, in vitro protein kinase assays were used to validate the 
interactions to the kinases as substrates. In summary, the study has identified substrates that are 
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directly phosphorylated by PfPK6, and demonstrated that the identified proteins are not directly 
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CHAPTER 1: INTRODUCTION 
1.1 Hypothesis and Specific Objectives 
  
 
 Malaria is a prevalent and life-threatening disease in the developing world caused by 
Plasmodium parasites that are spread through the bites of infected mosquito vectors. Every year 
3.4 billion people or roughly half of the world’s population is at risk of infection [2]. Of the 5 
malaria species that infect humans, Plasmodium falciparum is most virulent and is responsible 
for approximately 1 million deaths annually, predominantly affecting children in sub-Saharan 
Africa [3].  Mortality rates are falling due to increased prevention and control measures, but drug 
resistance to available antimalarials is widespread. Therefore, there is a need for better 
understanding the molecular mechanisms of the Plasmodium falciparum cell cycle, which would 
identify novel drug targets [4].  Protein kinases are key signaling molecules that regulate various 
steps in eukaryotic cell cycle.  The intent of this work is to explore protein kinases believed to be 
important in the cellular growth and proliferation of Plasmodium falciparum. Further 
investigation into the unique cell cycle and molecular mechanisms governing it may identify 
novel potential therapeutic targets. A global phosphoproteomics analysis done by our lab has 
identified several putative MAPK/CDK substrates. These substrates were identified by 
examining all phosphorylation events for the occurrence of proline-directed Ser/Thr 
phosphorylated peptides. 206 peptides were identified and further filtered to distinguish only 
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those containing the pS/T-P-X-K/R motif, a strong consensus CDK sequence. This method 
revealed 45 polypeptides as potential Plasmodium CDK substrates. Another technique used to 
identify substrates was by utilizing PTMScan® Direct immunoprecipitation. This method isolated 
proteins containing post-translational modifications (PTM), specifically those phosphorylated at 
the CDK consensus sequence [4]. The proposed work plans to determine the ability of 
Plasmodium falciparum CDK-like kinases to utilize four of the previously identified potential 
substrates. Specifically, CDK-related kinases PfPK5, PfPK6, and Pfmrk will be tested against 
putative substrates in order to gain a better understanding of their role in the P. falciparum 
intraerythrocytic cell cycle. In-vitro kinase assays will classify which of the predicted substrates 
can be utilized by the specific CDK-like kinases and to what extent they are employed. 
 This study will elucidate the mechanism of action through defining physiological 
substrates in the important CDK-like kinase phosphorylation cascade. It will allow us to see 
what families of proteins these kinases interact with, what it controls or is controlled by, and 
many other complex cellular interactions that may divulge information about Plasmodium 
falciparum’s cellular cycle. This will in turn generate information on growth, regulation, and 
defining drug targets of the parasite. 
 
1.2 Literature Review 
1.2.1 Plasmodium falciparum: The Most Clinically Significant Malaria Parasite  
 Malaria is transmitted to humans through the bites of infected Anopheles mosquitoes, and 
to feeding mosquitoes through infected human erythrocytes, propagating its unique three-stage 
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life cycle. From approximately 400 global species of Anopheles, about 60 are natural malaria 
vectors [5].  This life cycle consists of Plasmodium invasion from the mosquito midgut to the 
human liver, and subsequent progression to human erythrocytes. The malaria parasite life cycle 
is among the most complicated of any organism, with its intricacy impeding the development of 
a neutralizing vaccine. It is characterized by the ability to change its molecular makeup and 
cellular structure, and the capacity to develop intra- and extracellular niches within host 
organisms [6]. 
 Currently, humans can only be infected by five species of Plasmodium: Plasmodium 
ovale, Plasmodium malariae, Plasmodium knowlesi, Plasmodium vivax, and the most virulent 
and medically important species Plasmodium falciparum. Clinical complications of Plasmodium 
falciparum malaria include fever, lactic acidosis, anemia, and in severe cases coma and death 
[7]. Seizures, hypoglycemia, and severe anemia depict manifestations of severe malaria in 
children, whereas jaundice, pulmonary edema, and renal failure are more common in adult 
patients [8]. There have traditionally been two arms upon which disease control has relied: 
prevention of contact with humans (via removal of mosquito breeding sites, insecticides, screens, 
and bednets impregnated with insecticides), and effective case management (via antimalarials 
such as chloroquine). Extensive deployment of antimalarial drugs has provided massive selection 
pressure on human malaria parasites to evolve mechanisms of resistance [9]. Poor understanding 
of host immune response aswell as Plasmodium antigenic diversity have created substantial 
barriers to generating an effective blood stage vaccine. Two mechanisms, antigenic variation and 
allelic polymorphisms, are responsible for the presentation of antigenic diversity [9]. Expression 
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of alternative forms of antigen called Plasmodium falciparum erythrocyte membrane protein one 
(PfEMP1) throughout clonal lineage encompasses classical antigenic variation. The different 
forms are encoded by 60 var genes within the parasite genome. By cycling through these surface 
proteins, host immune response to previously expressed antigen can be avoided by parasite. The 
system by which these proteins are expressed is mutually exclusive, where only one var gene is 
expressed at any given time, and switching to a new variant when the host has mounted an 
effective response, P. falciparum is able to maximize the utility of its variant antigen repertoire 
[10]. Allelic polymorphisms, likely rising from host immune selection, are also a source of 
antigenic diversity. Merozoites also exhibit phenotypic variation in expression of functional 
ligands that bind to specific erythrocyte receptors. This provides mechanisms to counteract 
polymorphic nature of the red blood cell surface and escape immune detection [9].  For this 
reason it is important to investigate the molecular mechanisms of the malaria life cycle to 
elucidate and explore potential novel drug therapies that could counteract these pathogenic 
safeguards. 
1.2.2 P. falciparum’s Unique Life Cycle 
  Transmission between mosquitoes and humans involves a notable series of 
morphological transformations. The three stages of the malaria life cycle include sporogony, 















Figure 1: Plasmodium Life Cycle 
Figure publically available at http://www.cdc.gov/dpdx/malaria/index.html 
 
In the midgut lumen of bloodfed mosquitoes, the ookinete develops from a zygote and is the 
direct product of fertilization between a male and female gametocyte. This lone sexual 
replication stage in the malaria life cycle serves as a bottleneck, with each ookinete directly 
depending on individual fertilization events [6]. The ookinetes then traverse the midgut epithelial 
cell layer to reach the basal lamina, where they become immobile and transform into oocysts. 
The oocysts grow extracellularly and results in the formation of sporozoites, which are released 
in the mosquito body and invade salivary glands. When an infected mosquito bites its host, it 
releases these sporozoites to the human blood stream where they are directed to the liver and 
invade hepatocytes. In the liver stage, sporozoites grow and undergo asexual replication within a 
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parasitophorous vacuole that leads to a 10,000-fold amplification of parasite numbers, 
culminating in the release of merozoites into the circulatory blood stream [11]. Each merozoite is 
equipped to escape the remnants of its host red blood cell, find and attach to a fresh one, invade, 
and rapidly restart feeding. They contain the membranous vesicles rhoptries, micronemes, and 
dense granules that each discharge their contents during invasion and change the shape and 
composition of the invaded red blood cell membrane [12]. After invasion, the parasite undergoes 
a 48-hour cycle of asexual replication and division separated into three morphological stages: 
ring, trophozoite, and schizont. In the ring stage, the parasite begins feeding on the surrounding 
erythrocyte through a small, dense ring at its surface. Small portions of red blood cell cytosol are 
pulled in through this structure and digested within vacuoles contained in the parasite.  As it 
grows, the ring eventually changes shape into a more rounded or irregular trophozoite. In the 
trophozoite stage (~20-38 hours after invasion), the parasite is at its most metabolically active 
and growing rapidly, while concurrently altering the erythrocyte by exporting parasitic proteins 
to the cytosol and surface. Host RBC hemoglobin is digested extensively in a cytostome-derived 
vesicle mediated process. As hemoglobin is depleted, the parasite converts heme derivative into 
hemozoin crystals, which it stores within the pigment vacuole through the erythrocytic phase. 
Synthesis of molecules needed for parasite replication occur in the late phase of this stage [13]. 
The schizont stage (~38-48 hours post-invasion) is characterized by multiple rounds of 
acytokinetic nuclear division, generating merozoites that are clustered within the parasitophorous 
vacuole. Apical organelle secretions from newly formed merozoites breach the parasitic and red 
blood cell membranes and they proceed to infect new blood cells and replicate asexually [14]. To 
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propagate from one infected human to the next, merozoites from a precommitted schizont form 
gametocytes of the same sex, which replicate in the mosquito midgut after a blood meal [15].  
1.2.3 Identification of the P. falciparum Kinome 
 There is a pressing need for the development of new antimalarials with novel modes of 
action. Plasmodium falciparum has a relatively small kinome of <100 kinases, a number of 
which have been shown to be essential to the staggeringly complex life cyle of Plasmodium 













Figure 2: The Plasmodium Kinome 
 
 8 
1.2.3.1 Cyclin-dependent Protein Kinases 
 Cyclin-dependent kinases (CDKs) are a group of enzymes that play a crucial role in 
cellular mechanisms such as transcription, DNA replication, cell cycle progression and repair, 
apoptosis, and differentiation [16]. It is expected that P. falciparum CDKs function likewise. A 
wide variety of diseases are caused by abnormalities in regulation of CDKs. CDKs are the 
current focus of investigation in various medical studies as potential drug targets for this reason. 
CDKs function by binding a cognate cyclin to enter a partially active state. This partially active 
state displaces the “T-loop” which had its catalytic site sterically hindered during the inactive 
state [17].   A CDK activating complex (CAK) then phosphorylates a conserved threonine 
residue within the activation loop, fully activating the CDK (Fig. 3).  
 
 
Figure 3: CDK Activation 
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Due to their highly conserved nature and their role in cell growth, CDKs are attractive targets for 
therapeutic intervention. The active forms of CDKs are heterodimers consisting of a catalytic 
serine/threonine kinase subunit and a regulatory subunit, usually the cognate cyclin. The function 
of active CDK is to catalyze the phosphoryl transfer of γ-phosphate from adenosine-5’-
triphosphate (ATP) to a serine or threonine hydroxyl in the protein substrate [18]. Using 
homology-based PCR and database mining, several CDKs and cyclins have been identified in P. 
falciparum [19]. Although multiple CDKs and cyclins have been identified in P. falciparum, the 
mechanisms by which these molecules regulate activity within the parasite is not currently 
understood. Furthermore, the substrates of specific CDKs and CDK regulation mechanisms of 
the non-canonical malarial cell cycle have yet to be determined. Six CDK-related protein kinases 
have so far been identified in P. falciparum: PfPK5, PfPK6, Pfmrk, Pfcrk-1, Pfcrk-3, and Pfcrk-
4. This research will focus specifically on PfPK5, PfPK6, and Pfmrk. 
1.2.4 P. falciparum Protein Kinase 5 
 Plasmodium falciparum Protein Kinase 5 (PfPK5) is the best-characterized member of 
the P. falciparum CDK family. It is a putative homologue of p34cdc2 cyclin-dependent kinase 
required for both entry into S-phase and mitosis in fission yeast, and was the first CDK-like 
kinase characterized in P. falciparum. Homology searches have shown that PfPK5 contains 60% 
identity to CDK1 (human cdc2) and CDK5 [20]. PfPK5 co-localizes with the nuclear stain DAPI 
at the onset of schizogony, with expression and kinase activity peaking 36 hours post-invasion at 
the schizont stage [21]. In vitro, PfPK5 displays cyclin binding promiscuity and can be activated 
 10 
by mammalian p25, cylin A, and cyclin H (cognate regulators of CDK5, CDK1/2, and CDK7 
respectively) [22]. 
1.2.5 P. falciparum Protein Kinase 6 
Plasmodium falciparum protein kinase 6 (PfPK6) is a novel protein kinase originally 
isolated by differential display RT-PCR (DDRT-PCR) with shared homology in sequence to 
mitogen activated protein kinases (MAPKs) and to cyclin dependent kinases (CDKs) [23]. The 
similarity of the catalytic domain of PfPK6 to CDK2 and MAPK is 57.3% and 49.6%, 
respectively [23]. Although PfPK6 shares sequence homology with CDKs, there is evidence of 
PfPK6 acting as a cyclin-independent kinase. In the absence of a cyclin, the recombinant PfPK6 
shows significant auto-phosphorylation and phosphorylation of the control substrate Histone. 
Activity of this kinase is not augmented by cyclins. PfPK6 may be a unique cyclin-independent 
CDK whose regulation is not determined by the binding of a cognate partner. Peak expression 
levels were observed at the trophozoite stage [23]. 
1.2.6 P. falciparum MO15-related Protein Kinase 
 Plasmodium falciparum MO15-related protein kinase (Pfmrk) has also been 
isolated. Pfmrk displays the most sequence identity (46%) to human CDK7 of all of the 
mammalian CDKs with 62% similarity [24]. Although seemingly homologous to CDK7, the 
CAK-like activity shown in this protein has yet to be observed in Pfmrk [24]. It is expressed 
throughout both the trophozoite and schizont plasmodial stages of development. Unlike PfPK6, 
in the absence of a cyclin binding partner, kinase activity is minimal [25]. Once the experiment 
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has been run to completion, we will have a more definitive answer for the relationship of CDK-
like kinases to the rest of the malarial biochemical pathway. 
1.2.7 Putative Substrates 
 Four previously identified putative substrates were chosen to be tested against CDK-like 
kinases: MAL7P1.38, PF11_0332, PF10_0047, and PFC0805w. MAL7P1.38 has been identified 
as a regulator of chromosome condensation. PF10_0047 functions as an RNA binding protein. 
PF11_0332 and PFC0805w both are putative nucleic acid binding proteins. Each contains the 
consensus CDK pS/T-P-X-K/R motif. MAL7P1.38 and PF11_0332 were identified utilizing the 
motif analysis of phosphoproteomic data. PF10_0047 and PFC0805w were recognized 
employing PTMScan® Direct Immunoprecipitation. Analysis of these proteins’ ability to be 
directly phosphorylated by our CDK-like kinases will provide insight into the molecular 
pathways utilized by these important cellular regulators.   
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CHAPTER 2: ELUCIDATING THE FUNCTIONS OF PLASMODIUM 
FALCIPARUM PROTEIN KINASES THROUGH SUBSTRATE 
CHARACTERIZATION  
2.1 Materials and Methods 
 Methods that were employed in this research included cloning, protein expression, 
purification, and kinase assays. Recombinant kinases were purified utilizing a pGEX6P-1 vector 
and GST-tagged batch purification. After analyzing global phosphoproteomic data and 
PTMScan® Direct data, which was performed previously in our lab, we identified a number of 
putative MAPK/CDK substrates. Protocol used for this procedure was followed as previously 
described [4].  We generated His-tagged constructs of the potential substrates to investigate if 
any of these proteins are substrates of the CDK-like kinases in question. Truncated versions of 
the substrates (~1500 base pairs while ensuring the presence consensus motif) were cloned, due 
to their large size. EMD Millipore manufacturer’s instructions were used to clone the following 
proteins into the pET30 EK/LIC vector: MAL7P1.38, PF11_0332, PF10_0047, and PFC0805w. 
All ORFs were sequence confirmed prior to further use. The potential substrates were expressed 
in competent BL21-CodonPlus (RIPL) cells (Stratagene) afterwhich HisLink resin was used to 
purify the soluble fraction by affinity chromatography following the manufacturer’s instructions 
(Promega).  
2.1.1 Expression of Kinases and Putative Substrates 
 In order to express kinases and substrates used in this study, recombinant vectors were 
transformed into BL21-CodonPlus (RIPL) cells (Stratagene). All kinases and Pfcyc-1 utilized a 
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pGEX6P-1 vector containing a GST-tag. All putative substrates employed were cloned into a 
pET30 EK/LIC vector with a HisLink tag. A 5 mL culture of each transformation was incubated 
at 37°C overnight and added to 500 mL LB. Cultures were grown at 37°C until OD was ~0.5, 
cooled to 20°C for 1 hour, induced with 0.5 mM IPTG, and incubated overnight at 20°C.  
2.1.2 Purification of CDK-like Kinases 
 Cultures were harvested by centrifuging at 10,000 rpm, 4°C for 20 minutes. Supernatant 
was removed and the pellet was resuspended in 10 mL of 300 mM Mk buffer (40mM Hepes pH 
7.4, 300mM NaCl, 0.02% monothioglycerol) and 100 µL of 100x HALT protease inhibitor. Cell 
lysis was performed by adding 1mg/mL of lysozyme and incubating on ice for 30 minutes, 
inverting samples every 5 minutes. Cells were then sonicated with a 30 second pulse, incubating 
on ice for one minute in between pulses, until 80% lysis was achieved, monitored by 
spectrophotometer OD 600 values. After lysis, samples were centrifuged at 25,000 rpm for 20 
minutes at 4°C. The supernatant was added to 3 mL of 50% Glutathione agarose slurry, 
incubated at 4°C overnight, then added to a gravity column. Proteins were eluted using buffer 
consisting of 40 mM Hepes pH 7.4, 200 mM NaCl, 0.02% monothioglycerol, and 10mM 
reduced glutathione. 20 µL aliquots of each elution were collected for SDS-PAGE analysis to 
ensure purity of samples. Elutions containing pure protein were concentrated using 10,000 
MWCO PES vivaspin 2 concentrators (Sartorius) and buffer exchanged. 
2.1.3 Purification of Putative Substrates 
 Cultures were harvested by centrifuging at 10,000 rpm, 4°C for 20 minutes. Supernatant 
was removed and the pellet was resuspended in 10 mL of HisLink binding buffer (100 mM 
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Hepes pH 7.5, 10 mM Imidazole, 300 mM NaCl) and 100 µL of 100x HALT protease inhibitor. 
Cell lysis was performed by adding 1mg/mL of lysozyme and incubating on ice for 30 minutes, 
inverting samples every 5 minutes. Cells were then sonicated with a 30 second pulse, incubating 
on ice for one minute in between pulses, until 80% lysis was achieved, monitored by 
spectrophotometer OD 600 values. After lysis, samples were centrifuged at 25,000 rpm for 20 
minutes at 4°C. The supernatant was added to 3 mL of 50% HisLink resin (Promega), incubated 
at 4°C overnight, then added to a gravity column. Proteins were eluted using buffer consisting of 
100 mM Hepes pH 7.5 and 250 mM Imidazole. 20 µL aliquots of each elution were collected for 
SDS-PAGE analysis to ensure purity of samples. Elutions containing pure protein were 
concentrated using 10,000 MWCO PES vivaspin 2 concentrators (Sartorius) and buffer 
exchanged. 
2.1.4 In vitro Kinase Assays  
 Kinase reactions to measure CDK-like kinase auto-phosphorylation and activity toward 
the potential substrates were performed by using 1μg of recombinant kinase and increasing 
concentrations (1μg, 2.5μg, 5μg, 10μg) of recombinant substrate in a total volume of 30μl as 
described previously [26]. A standard kinase buffer was used, consisting of 20mM Tris/HCl (pH 
7.5), 20mM MgCl2, 2mM MnCl2, 10μM ATP, and 5μCi (γ-32P). Kinase reactions were incubated 
for 30 minutes at 30°C and stopped by the addition of 5X gel loading buffer. Kinase reactions 
were then loaded on a 12% SDS-polyacrylamide gel. Coomassie blue stain was used to visualize, 
with a mixture of 30% methanol and 10% glacial acetic acid solution used to destain overnight. 
Gels were then dried and exposed for autoradiography. Signal intensity values were obtained and 
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analyzed, normalizing the kinase buffer control as the 0% value and the phosphorylation of 
Histone as the 100% value for each kinase. The kinases’ capability to directly phosphorylate 
putative substrates were determined by percent signal intensity, after normalization, compared to 
the 100% phosphorylation value of Histone by each kinase tested. All assays were performed 
independently and in duplicate to ensure reliability of findings. 
2.2 Results and Discussion 
To investigate the role of CDK-like kinases PfPK5, PfPK6, and Pfmrk in Plasmodium 
falciparum we performed in vitro kinase assays to identify substrates of each. 1μg of 
recombinant kinase and regulatory cyclin along with 1μg, 2.5 μg, 5 μg, or 10 μg of substrate was 
used for each assay condition. Each assay was performed twice independently using Histone as a 
control substrate. PfPK5 showed no significant phosphorylation of putative regulator of 
chromosome condensation (MAL7P1.38), PF11_0332, putative RNA binding protein 
(PF10_0047), or PFC0805w at concentrations of 1µg, 2.5µg, 5µg, or 10µg. It did, however, 
demonstrate phosphorylation of the controls susbtrate Histone as well as robust 
autophosphorylation, which displayed a decreasing pattern as substrate concentrations increased. 
This may suggest that although substrates are not directly phosphorylated by PfPK5, their 
interaction somehow inhibits autophosphorylation.  Pfmrk also did not show phosphorylation of 
any of the potential substrates at any of the tested concentrations.  It maintained steady 
autophosphorylation activity across all substrate concentrations, indicating that it is not affected 
by interaction with any of the putative substrates tested. PfPK6 displayed direct phosphorylating 
activity of MAL7P1.38, PF11_0332, PF10_0047, and PFC0805w across all concentrations. It 
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clearly phosphorylated putative regulator of chromosome condensation (MAL7P1.38) greater 
than it’s own auto-phosphorylation. PfPK6 was also able to phosphorylate RNA binding protein 
(PF10_0047) to a lesser extent. The ability of PfPK6 to phosphorylate a putative regulator of 
chromosome condensation and a RNA binding protein is suggestive of its nuclear function 
although the nuclear localization of PfPK6 is not evident. It is possible that these substrates of 
PfPK6 shuttle in and out of the nucleus. These results confirm previous PfPK6 studies done at 
our lab, which also demonstrated the ability of PfPK6 to phosphorylate the above-mentioned 
substrates. All kinases demonstrated autophosphorylation to an extent, with PfPK5 displaying 
the most robust activity. 
2.3 Conclusions 
Although CDK-like kinases show a highly conserved nature, their functions can be very 
different, as evidenced in this study. Plasmodium falciparum undergoes an extremely 
complicated developmental cycle with fluctuations between cell proliferation and stages of 
withdrawal in both human and insect hosts. The progression between cell cycle stages are 
traditionally known to be regulated in eukaryotic cells by cyclin-dependent kinases. As such, a 
similar mechanism is expected in the complex Plasmodium life cycle. To better understand the 
function of Plasmodium falciparum CDK-like kinases, we investigated the utilization of putative 
CDK/MAPK substrates identified by our phosphoproteomic dataset and PTMScan® Direct by 
our purified Plasmodium CDK-like kinases. Of these CDK-like malaria parasite kinases, PfPK6 
is the only one shown to have cyclin-independent activity. This functional divergence from the 
other kinases tested may be explained by a structural distinction allowing for different 
interactions from typical CDK-related kinases. Although PfPK6 has the most structural 
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homology to CDKs, perhaps it can be classified in a different manner after observing its 
function. This study revealed substrates tested to be specific to PfPK6, whereas interaction with 
PfPK5 and Pfmrk showed no activity.  In conclusion, this study has made significant progress in 
defining catalytic mechanism and the cellular roles of CDK-like malaria parasite kinases, most 
notably PfPK6. 
 
Figure 4: Substrate Controls 
(A) Coomasie blue stained gel of the in vitro substrate control assay run with 5µg of substrate in 
the absence of kinase. (B) Phosphoimage of the in vitro kinase assay gel depicted in (A). 
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Figure 5: PfPK5 Kinase Assay Controls 
(A) Coomasie blue stained gel of the PfPK5 in vitro kinase assay controls. (B) Phosphoimage of 




Figure 6: PfPK5 Kinase Assay 
(A) Coomasie blue stained gel of the PfPK5 in vitro kinase assay vs. MAL7P1.38. (B) 
Phosphoimage of the in vitro kinase assay gel depicted in (A). (C) Coomassie blue stained gel of 
the PfPK5 in vitro kinase assay vs. PF11_0332. (D) Phosphoimage of the in vitro kinase assay 
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gel depicted in (C). (E) Coomasie blue stained gel of the PfPK5 in vitro kinase assay vs. 
PF10_0447. (F) Phosphoimage of the in vitro kinase assay gel depicted in (E). (G) Coomasie 
blue stained gel of the PfPK5 in vitro kinase assay vs. PF10_0447. (H) Phosphoimage of the in 
vitro kinase assay gel depicted in (G). (I) Normalized signal intensity values. Master mix alone 




     Figure 7: PfPK6 Kinase Assay Controls 
(A) Coomasie blue stained gel of the PfPK6 in vitro kinase assay controls. (B) Phosphoimage of 
the in vitro kinase assay gel depicted in (A). 
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  Figure 8: PfPK6 Kinase Assay 
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(A) Coomasie blue stained gel of the PfPK6 in vitro kinase assay vs. MAL7P1.38. (B) 
Phosphoimage of the in vitro kinase assay gel depicted in (A). (C) Coomassie blue stained gel of 
the PfPK6 in vitro kinase assay vs. PF11_0332. (D) Phosphoimage of the in vitro kinase assay 
gel depicted in (C). (E) Coomasie blue stained gel of the PfPK6 in vitro kinase assay vs. 
PF10_0447. (F) Phosphoimage of the in vitro kinase assay gel depicted in (E). (G) Coomasie 
blue stained gel of the PfPK6 in vitro kinase assay vs. PF10_0447. (H) Phosphoimage of the in 
vitro kinase assay gel depicted in (G). (I) Normalized signal intensity values. Master mix alone 




         Figure 9: Pfmrk Kinase Assay Controls 
(A) Coomasie blue stained gel of the PfPK6 in vitro kinase assay controls. (B) Phosphoimage of 
the in vitro kinase assay gel depicted in (A). 
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Figure 10: Pfmrk Kinase Assay 
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(A) Coomasie blue stained gel of the Pfmrk in vitro kinase assay vs. MAL7P1.38. (B) 
Phosphoimage of the in vitro kinase assay gel depicted in (A). (C) Coomassie blue stained gel of 
the Pfmrk in vitro kinase assay vs. PF11_0332. (D) Phosphoimage of the in vitro kinase assay 
gel depicted in (C). (E) Coomasie blue stained gel of the Pfmrk in vitro kinase assay vs. 
PF10_0447. (F) Phosphoimage of the in vitro kinase assay gel depicted in (E). (G) Coomasie 
blue stained gel of the Pfmrk in vitro kinase assay vs. PF10_0447. (H) Phosphoimage of the in 
vitro kinase assay gel depicted in (G). (I) Normalized signal intensity values. Master mix alone 
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